Frailty and Risk of Serious Infections in Biologic-treated Patients With Inflammatory Bowel Diseases.

ABSTRACT:

Background

Identifying biologic-treated patients with inflammatory bowel diseases (IBDs) at higher risk of serious infections is a priority. We conducted a retrospective cohort study evaluating frailty and risk of serious infections in biologic-treated patients with IBD.

Methods

Using an administrative claims database, we identified biologic-treated patients with IBD between 2014 and 2018 with follow-up 1 year before and after treatment initiation. Using a validated claims-based hospital frailty risk scoring system, patients were classified as frail and nonfrail. We compared the risk of serious infections (infections requiring hospitalization) between frail and nonfrail patients using Cox proportional hazard analysis adjusting for age, comorbidities, disease characteristics,

SUBMITTER: Singh S 

PROVIDER: S-EPMC8522787 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature